Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings

HU Tie-min; CHU Hui-song; TIAN Tian; WANG Kun-peng; YANG Guo-jun; YANG Li-jun; WANG Wei-xing

doi:10.13798/j.issn.1009-153X.2017.08.012

Abstract：Objective To investigate the expressions of adisintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) in the gliomas tissues and their clinical meanings. Methods The expression levels of ADAM17 and EGFR were determined by western blot and immunohischemical technique in 68 samples of fresh gliomas tissues, of which, 42 were derived from the high-grade gliomas and 26 from the low-grade gliomas, and in 10 samples of normal brain tissues derived from the patients with traumatic brain injury undergoing surgery. The relationship between ADAM17 and EGFR was analyzed. Results The expression level of ADAM17 was significantly higher in high-grade gliomas than low-grade gliomas (P<0.01), of which the expression level of ADAM17 was significantly higher than the normal brain tissues (P<0.01). The EGFR protein was not detected in the normal brain tissues. The expression level of EGFR was significantly higher in high-grade gliomas than low-grade gliomas (P<0.01). The positive expression rate of ADAM17 [95.24%(40/42)] was significantly higher in high-grade gliomas than that [61.54%(16/26)] in low-grade gliomas, of which the positive expression rate of ADAM17 was significantly higher than that [20.00% (2/10)] in the normal brain tissues (P<0.01). The positive expression rate of EGFR was significantly higher in high-grade gliomas than that in low-grade gliomas (P<0.01). The expression of ADAM17 was positively related to the expression of EGFR (P<0.01). Conclusions The expressions of EGFR and ADAM17 rise as the malignant degree of brain glioma increases. It is suggested that the high expression levels of ADAM17 and EGFR are closely related to proliferation of glioma cells.